Intriguingly, previous findings demonstrating an association between trastuzumab-mediated ADCC and a favourable outcome in operable HER2-overexpressing BC patients supported the importance of an uncompromised immune function in patients with early-stage tumors [6, 11]. Here, ERBB2 is linked to breast cancer.